- Home
- CMA vs LEGN Comparison
CMA vs LEGN Comparison
Compare CMA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMA | LEGN |
|---|---|---|
| Founded | 1849 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CMA | LEGN |
|---|---|---|
| Price | $89.28 | $22.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 22 | 13 |
| Target Price | ★ $71.86 | $69.67 |
| AVG Volume (30 Days) | 1.3M | ★ 2.5M |
| Earning Date | 01-21-2026 | 11-12-2025 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | ★ 30.50 | N/A |
| EPS | ★ 5.23 | N/A |
| Revenue | ★ $3,234,000,000.00 | $909,045,000.00 |
| Revenue This Year | $6.42 | $68.83 |
| Revenue Next Year | $3.03 | $51.27 |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | 2.31 | ★ 74.75 |
| 52 Week Low | $48.12 | $22.28 |
| 52 Week High | $90.44 | $45.30 |
Technical Indicators
Market Signals| Indicator | CMA | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 79.92 | 21.96 |
| Support Level | $83.48 | $26.43 |
| Resistance Level | $90.44 | $28.97 |
| Average True Range (ATR) | 1.72 | 1.57 |
| MACD | 0.88 | -0.43 |
| Stochastic Oscillator | 92.92 | 0.91 |
Price Performance
Historical ComparisonAbout CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.